BridgeBio Oncology Therapeutics Ownership | Who Owns BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics Ownership Summary

BridgeBio Oncology Therapeutics is owned by 18.56% institutional investors, 24.05% insiders, and 57.39% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 8.87% of BBOT shares.

BBOT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	BridgeBio Oncology Therapeutics	18.56%	24.05%	57.39%
Sector	Healthcare Stocks	232.52%	10.72%	-143.24%
Industry	Biotech Stocks	384.56%	10.59%	-295.14%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock funding, inc. /de	2.08M	8.87%	$26.10M
Vanguard group	791.10K	3.37%	$9.90M
Aisling capital management lp	564.63K	2.40%	$7.07M
Geode capital management	561.99K	2.39%	$7.04M
Td asset management	117.15K	0.50%	$1.47M
Goldman sachs group	94.65K	0.40%	$1.19M
Ubs group	93.37K	0.40%	$1.17M
Renaissance	74.30K	0.32%	$930.24K
Bnp paribas arbitrage, snc	26.47K	0.11%	$331.43K
Bit capital gmbh	25.00K	0.11%	$313.00K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Aisling capital management lp	564.63K	1.48%	$7.07M
Bit capital gmbh	25.00K	0.01%	$313.00K
Renaissance	74.30K	0.00%	$930.24K
Td asset management	117.15K	0.00%	$1.47M
Geode capital management	561.99K	0.00%	$7.04M
Blackrock funding, inc. /de	2.08M	0.00%	$26.10M
Bnp paribas arbitrage, snc	26.47K	0.00%	$331.43K
Ubs group	93.37K	0.00%	$1.17M
Cibc private wealth group	5.00K	0.00%	$62.60K
Vanguard group	791.10K	0.00%	$9.90M

Top Buyers

Holder	Shares	% Assets	Change
Vanguard group	791.10K	0.00%	143.50K
Goldman sachs group	94.65K	0.00%	94.65K
Renaissance	74.30K	0.00%	74.30K
Ubs group	93.37K	0.00%	41.14K
Blackrock funding, inc. /de	2.08M	0.00%	36.28K

Top Sellers

Holder	Shares	% Assets	Change
Silverarc capital management	-	-	-457.41K
Td asset management	117.15K	0.00%	-12.91K
China universal asset management	-	-	-5.00K
Fny investment advisers	-	-	-100.00
Aisling capital management lp	564.63K	1.48%	-

New Positions

Holder	Shares	% Assets	Change	Value
Goldman sachs group	94.65K	0.00%	94.65K	$1.19M
Renaissance	74.30K	0.00%	74.30K	$930.24K
Bnp paribas arbitrage, snc	26.47K	0.00%	26.47K	$331.43K
Bit capital gmbh	25.00K	0.01%	25.00K	$313.00K
Cibc private wealth group	5.00K	0.00%	5.00K	$62.60K

Sold Out

Holder	Change
Fny investment advisers	-100.00
China universal asset management	-5.00K
Silverarc capital management	-457.41K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	10	-75.61%	4,364,186	-92.32%	18	0.03%	8	-80.49%	1	-
Sep 30, 2025	40	-	56,812,263	-	241	-	40	-	-	-

Insider Transactions Trends

Date	Buy	Sell
2025 Q4	-	-
2025 Q3	-	-

BBOT Ownership FAQ

Who Owns BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics shareholders are primarily institutional investors at 18.56%, followed by 24.05% insiders and 57.39% retail investors. The average institutional ownership in BridgeBio Oncology Therapeutics's industry, Biotech Stocks , is 384.56%, which BridgeBio Oncology Therapeutics falls below.

Who owns the most shares of BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics’s largest shareholders are Blackrock funding, inc. /de (2.08M shares, 8.87%), Vanguard group (791.1K shares, 3.37%), and Aisling capital management lp (564.62K shares, 2.40%). Together, they hold 14.64% of BridgeBio Oncology Therapeutics’s total shares outstanding.

Does Blackrock own BridgeBio Oncology Therapeutics?

BlackRock is not among the top 10 institutional shareholders of BridgeBio Oncology Therapeutics.

Who is BridgeBio Oncology Therapeutics’s biggest shareholder by percentage of total assets invested?

Aisling capital management lp is BridgeBio Oncology Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.48% of its assets in 564.62K BridgeBio Oncology Therapeutics shares, valued at 7.07M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools